Pharmaceuticals, Biotechnology and Life Sciences
Transgene confirms that the study’s primary
endpoint (objective response rate – ORR) on a minimum of 35 evaluable
patients will be reported in Q4 2019.
The LYRICA Pediatric Epilepsy Program is composed of six studies in
patients with epilepsy evaluating LYRICA as adjunctive therapy, five of
which have been completed.
Medicure Inc reported net loss for the quarter ended March 31, 2019 at $2.8 million compared to net income of $1.4 million for the quarter ended March 31, 2018.
Jakafi is the first and only FDA-approved treatment for patients with
steroid-refractory acute graft-versus-host disease (GVHD)
Veratrak, a UK-based software provider dedicated to transforming supply chains across the life science industry, said Wednesday in a press release that contract packaging organisation (CPO) Central Pharma has selected its platform to help it achieve digitised end-to-end visibility of its supply chain and improve collaboration.
Eli Lilly’s Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly’s rapid-acting insulin and need a lower-cost option, the company said Wednesday.
Mayne Pharma Group Limited got approval from the USFDA for Sorilux foam, 0.005% in adolescents, for treating plaque psoriasis of the scalp and body in patients 12 years and older.
Halozyme Therapeutics said Wednesday that argenx has selected a second target under the collaboration and license agreement the companies announced in February 2019.
Synlogic in clinical collaboration with Roche to explore Synlogic’s Synthetic Biotic medicine for advanced solid tumors
Global Healthcare Strategy Consulting Expert Sheldon Ng Joins Navigant to Bolster Life Sciences and Provider Collaboration